10-Q: Inhibrx Biosciences Q1 2026 Results: Pipeline Progress & Financial Update

Inhibrx Biosciences reports Q1 2026 results, highlighting clinical trial advancements for ozekibart and INBRX-106, alongside a strengthened balance sheet through debt financing.

Summary

• Inhibrx Biosciences reported a net loss of $33.4 million for the first quarter ended March 31, 2026, compared to a net loss of $43.3 million in the same period of 2025.
• Research and development expenses decreased by 32% to $25.2 million in Q1 2026 from $36.9 million in Q1 2025, primarily due to the completion of enrollment in certain clinical trials and manufacturing activities.
• General and administrative expenses remained relatively stable, decreasing slightly to $5.7 million in Q1 2026 from $6.0 million in Q1 2025.
• The company's cash and cash equivalents increased to $161.7 million as of March 31, 2026, from $124.2 million as of December 31, 2025.
• Significant progress was noted in clinical development, with interim data for ozekibart in colorectal cancer showing a 20% ORR and durable responses, and positive interim results for INBRX-106 in head and neck squamous cell carcinoma demonstrating a 44% ORR in combination with pembrolizumab.
• The company submitted a biologics license application to the FDA for ozekibart in conventional chondrosarcoma in April 2026.
• Inhibrx Biosciences secured $75.0 million in gross proceeds from the Term B Loans under the Amended 2025 Loan Agreement in March 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, driven by strong clinical data readouts for key pipeline assets and a strengthened financial position through debt financing, despite ongoing net losses.

Positives

• Ozekibart demonstrated a 20% Objective Response Rate (ORR) in combination with FOLFIRI for colorectal cancer, with nearly half of responses durable beyond 6 months, significantly outperforming historical standard of care response rates (1-6%).
• Ozekibart in Ewing sarcoma showed a 64.5% ORR and an 87.1% disease control rate in a Phase 1/2 trial update, with one patient remaining progression-free for over two years.
• Ozekibart met its primary endpoint in a registrational trial for chondrosarcoma, achieving a 52% reduction in the risk of disease progression or death compared to placebo and more than doubling median PFS.
• INBRX-106 in combination with pembrolizumab for first-line head and neck squamous cell carcinoma showed a 44.0% ORR, a 22.6% absolute increase over the control arm (21.4% ORR), including three complete responses.
• The company submitted a biologics license application (BLA) to the FDA for ozekibart in conventional chondrosarcoma in April 2026.
• Cash and cash equivalents increased to $161.7 million as of March 31, 2026, providing a runway of at least 12 months.
• The company secured an additional $75.0 million in gross proceeds from the Term B Loans in March 2026, strengthening its financial position.

Negatives

• The company reported a net loss of $33.4 million for the first quarter of 2026.
• Research and development expenses, while decreased, remain substantial at $25.2 million for the quarter.
• The company has an accumulated deficit of $279.6 million as of March 31, 2026.
• Interest expense increased by 30% to $3.5 million in Q1 2026 from $2.7 million in Q1 2025 due to increased debt.
• Interest income decreased by 57% to $1.0 million in Q1 2026 from $2.3 million in Q1 2025, likely due to lower cash balances or interest rates.

Risks

• The company's ability to fund its operations for at least the next 12 months is based on current operating plans and assumptions that may prove incorrect, potentially leading to depletion of capital resources sooner than expected.
• Future capital needs may require equity offerings, which would dilute existing stockholders, or debt financings with restrictive covenants.
• The company may have to relinquish valuable rights or grant licenses on less favorable terms if it raises capital through strategic licensing or collaboration agreements.
• The inherent uncertainty of preclinical and clinical development means that timelines, success probabilities, and development costs can differ materially from expectations.
• The company relies on a limited number of third-party contract manufacturers for its raw materials and biologics, creating potential supply chain risks.
• The company is subject to significant debt obligations with a maturity date of January 1, 2030, and a substantial final payment due.
• The company's future liquidity and capital funding requirements depend on numerous factors, including the outcome of clinical trials, regulatory approvals, market acceptance, and the emergence of competing therapeutics.

Future Outlook

The company believes its existing cash and cash equivalents will be sufficient to fund operations for at least the next 12 months. Future funding is expected through equity offerings, debt financings, or other capital sources like collaborations and strategic transactions. The company anticipates continued increases in research and development expenses as it advances its therapeutic candidates, particularly into later-stage clinical development and potential commercialization.

Management Comments

• The company's current pipeline is focused on oncology.
• Ozekibart is a precisely engineered tetravalent death receptor 5 (DR5) agonist currently being evaluated in patients diagnosed with colorectal cancer, Ewing sarcoma, chondrosarcoma, and certain other solid tumor types.
• INBRX-106 is a hexavalent OX40 agonist currently being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab).
• We believe OX40 agonism has the greatest potential to drive cure in earlier-stage disease settings, where patients typically retain a more active and responsive immune system.
• We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development and support our preclinical programs.

Industry Context

StockSavvy.ai notes that Inhibrx Biosciences is operating in the highly competitive and capital-intensive biopharmaceutical sector, focusing on oncology. The company's strategy of leveraging proprietary protein engineering platforms to develop novel biologic therapeutic candidates aligns with industry trends towards targeted therapies and immuno-oncology. The positive clinical trial data for ozekibart and INBRX-106, if validated in later-stage trials, could position Inhibrx as a significant player in its target indications, particularly in areas with high unmet medical needs like chondrosarcoma and certain solid tumors.

Comparison to Industry Standards

• Ozekibart's ORR of 20% in combination with FOLFIRI for colorectal cancer, with durable responses, compares favorably to historical standard of care response rates of 1-6% for similar patient populations.
• In Ewing sarcoma, the observed 64.5% ORR and 87.1% disease control rate for ozekibart in combination with IRI/TMZ are strong preliminary results, especially considering the limited treatment options for advanced or metastatic disease.
• The achievement of a statistically significant PFS benefit for ozekibart in chondrosarcoma, with a 52% reduction in risk of progression or death, is a notable accomplishment as it is the first investigational therapy to demonstrate such a benefit in a randomized trial for this disease, which lacks approved systemic options.
• The 44.0% ORR for INBRX-106 in combination with pembrolizumab in first-line HNSCC represents a substantial improvement over the 21.4% ORR seen with pembrolizumab monotherapy, indicating a potential synergistic effect that aligns with industry efforts to enhance checkpoint inhibitor efficacy.

Legal Proceedings

• The Company is not party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Creditors and lenders are impacted by the company's debt obligations and its ability to meet covenants.
• Employees are subject to the company's financial performance and its ability to fund ongoing operations and development.
• Suppliers and contract manufacturers (CROs and CDMOs) are impacted by the company's payment terms and the ongoing nature of its development programs.

Next Steps

• Meet with the FDA in the second half of 2026 to discuss the potential for an accelerated regulatory pathway for ozekibart in fourth-line colorectal cancer and to discuss plans to initiate a first-line registrational trial in CRC.
• Complete enrollment in the Phase 1/2 trial of ozekibart in combination with IRI/TMZ for advanced or metastatic, unresectable, relapsed, or refractory Ewing sarcoma in the second half of 2026.
• Meet with the FDA in the second half of 2026 to discuss the potential for an accelerated regulatory pathway for ozekibart in Ewing sarcoma, if current response and duration trends continue.
• Begin the Phase 3 portion of the HexAgon study for INBRX-106 during the third quarter of 2026.
• Initiate a study for INBRX-106 in the perioperative setting in NSCLC later this quarter (Q2 2026).
• Explore combinations of INBRX-106 with agents that could benefit from T-cell costimulation, such as vaccines, T-cell engagers, and CAR-Ts.

Key Dates

Recommendation

The company is showing promising clinical development progress and has secured additional financing, which are positive indicators. However, the significant accumulated deficit, ongoing net losses, and the inherent risks associated with drug development and regulatory approval warrant a cautious approach. A 'hold' recommendation reflects the balance between potential upside from pipeline advancements and the substantial risks involved.

Keywords

Inhibrx Biosciences, Form 10-Q, Quarterly Report, Ozekibart, INBRX-106, Clinical Trials, Oncology, Biopharmaceutical, FDA, BLA, Oxford Finance, Loan Agreement, Net Loss, Research and Development